Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (311-320 of 516) with videos related to

Pageof 52
Sort By:
European Journal of Haematology|April 4, 2019
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studiesMeletios A Dimopoulos, Jacob P Laubach, Maria Asunción Echeveste Gutierrez, et al.
Blood Cancer Journal|June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering CommitteeShaji Kumar, Lawrence Baizer, Natalie S Callander, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaAnita D'Souza, Nina Shah, Cesar Rodriguez, et al.
Blood|September 2, 2011
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndromeAnita D'Souza, Suzanne R Hayman, Francis Buadi, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
American Journal of Hematology|June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.
Blood|December 24, 2005
Clinical implication of centrosome amplification in plasma cell neoplasmWee J Chng, Greg J Ahmann, Kim Henderson, et al.
Bone Marrow Transplantation|June 11, 2020
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosisNadine Abdallah, Surbhi Sidana, Angela Dispenzieri, et al.
Blood|August 28, 2010
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical featuresShaji Kumar, Angela Dispenzieri, Jerry A Katzmann, et al.
Pageof 52

Showing results (311-320 of 516) with videos related to

Sort By:
Pageof 52
European Journal of Haematology|April 4, 2019
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studiesMeletios A Dimopoulos, Jacob P Laubach, Maria Asunción Echeveste Gutierrez, et al.
Blood Cancer Journal|June 29, 2022
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering CommitteeShaji Kumar, Lawrence Baizer, Natalie S Callander, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaAnita D'Souza, Nina Shah, Cesar Rodriguez, et al.
Blood|September 2, 2011
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndromeAnita D'Souza, Suzanne R Hayman, Francis Buadi, et al.
Haematologica|August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myelomaPaul G Richardson, Brian G Durie, Laura Rosiñol, et al.
American Journal of Hematology|June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.
Blood|December 24, 2005
Clinical implication of centrosome amplification in plasma cell neoplasmWee J Chng, Greg J Ahmann, Kim Henderson, et al.
Bone Marrow Transplantation|June 11, 2020
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosisNadine Abdallah, Surbhi Sidana, Angela Dispenzieri, et al.
Blood|August 28, 2010
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical featuresShaji Kumar, Angela Dispenzieri, Jerry A Katzmann, et al.
Pageof 52